SEC Form 4 · accession 0001692747-26-000005
OnKure Therapeutics, Inc. · OKUR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason A. Leverone
Officer — Chief Financial Officer
Period of report
Sep 21, 2026
Accepted (ET)
Sep 23, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001637715
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2,F3 | Sep 21, 2026 | S | 302 | $2.9742 | D | 18,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
- F2This transaction was executed in multiple trades at prices ranging from $2.95 to $3.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.